{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["84(5)"],"submitter":["Tatman PD"],"pubmed_abstract":["<b>Background</b>  Epigenetics may predict treatment sensitivity and clinical course for patients with meningiomas more accurately than histopathology. Nonetheless, targeting epigenetic mechanisms is understudied for pharmacotherapeutic development for these tumors. The bio-molecular insights and potential therapeutic development of meningioma epigenetics led us to investigate epigenetic inhibition in meningiomas. <b>Methods</b>  We screened a 43-tumor cohort using a 139-compound epigenetic inhibitor library to assess sensitivity of relevant meningioma subgroups to epigenetic inhibition. The cohort was composed of 5 cell lines and 38 tumors cultured directly from surgery; mean patient age was 56.6 years ± 13.9 standard deviation. Tumor categories: 38 primary tumors, 5 recurrent; 33 from fe"],"journal":["Journal of neurological surgery. Part B, Skull base"],"pagination":["452-462"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10477014"],"repository":["biostudies-literature"],"pubmed_title":["High-Throughput Screening of Epigenetic Inhibitors in Meningiomas Identifies HDAC, G9a, and Jumonji-Domain Inhibition as Potential Therapies."],"pmcid":["PMC10477014"],"pubmed_authors":["Graner MW","Ormond DR","Tatman PD","Youssef AS","Wroblewski TH","Jensen RL","Fringuello AR","Foreman WB","Damek DM","Scherer SR","Lillehei KO"],"additional_accession":[]},"is_claimable":false,"name":"High-Throughput Screening of Epigenetic Inhibitors in Meningiomas Identifies HDAC, G9a, and Jumonji-Domain Inhibition as Potential Therapies.","description":"<b>Background</b>  Epigenetics may predict treatment sensitivity and clinical course for patients with meningiomas more accurately than histopathology. Nonetheless, targeting epigenetic mechanisms is understudied for pharmacotherapeutic development for these tumors. The bio-molecular insights and potential therapeutic development of meningioma epigenetics led us to investigate epigenetic inhibition in meningiomas. <b>Methods</b>  We screened a 43-tumor cohort using a 139-compound epigenetic inhibitor library to assess sensitivity of relevant meningioma subgroups to epigenetic inhibition. The cohort was composed of 5 cell lines and 38 tumors cultured directly from surgery; mean patient age was 56.6 years ± 13.9 standard deviation. Tumor categories: 38 primary tumors, 5 recurrent; 33 from fe","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2025-04-05T12:36:16.545Z","creation":"2025-04-05T12:36:16.545Z"},"accession":"S-EPMC10477014","cross_references":{"pubmed":["37671294"],"doi":["10.1055/a-1885-1257"]}}